Genetic and Engineering Biotechnology News - How to Find Drugs that Work Together - Patricia Fitzpatrick Dimond

 – October 18, 2013  –– 

In the October 9th issue of Science Translational Medicine, researchers at the Icahn School of Medicine at Mount Sinai reported that by adding a second drug to the diabetes drug rosiglitazone, adverse cardiac drug effects in diabetic patients dropped greatly. They made the discovery though analyzing data from the FDA Adverse Event Reporting System (FDAERS) to discover whether second drugs could lower the rate of heart attacks. "We found that the drug emanative, often given along with rosiglitazone to get better control of blood glucose, also very substantially reduced the heart attack rate in rosiglitazone users," said study investigator Ravi Iyengar, PhD, Professor of Oncological Sciences, Psychiatry, Pharmacology and Systems Therapeutics, and Director of the Experimental Therapeutics Institute of the Systems Biology Center at the Icahn School of Medicine at Mount Sinai.
-Dr. Ravi Iyengar, Professor, Oncological Sciences, Psychiatry, Pharmacology and Systems Therapeutics, Director, Experimental Therapeutics Institute, Systems Biology Center, Icahn School of Medicine at Mount Sinai
Learn more